Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior.
D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D065092:Antidiuretic Hormone Receptor Antagonists; D001007:Anxiety / Q000523:psychology*; D001127:Arginine Vasopressin / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects*; D003216:Conditioning, Operant / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009043:Motor Activity / Q000187:drug effects; D010052:Ovariectomy; D051381:Rats; D017207:Rats, Sprague-Dawley; D017483:Receptors, Vasopressin / Q000235:genetics; D021641:Recognition, Psychology / Q000187:drug effects; D012919:Social Behavior; D013141:Spiro Compounds / Q000494:pharmacology; D014667:Vasopressins / Q000378:metabolism; D014828:Vocalization, Animal / Q000187:drug effects
D014151:Anti-Anxiety Agents; D065092:Antidiuretic Hormone Receptor Antagonists; C542688:JNJ-17308616; D017483:Receptors, Vasopressin; D013141:Spiro Compounds; D014667:Vasopressins; D001127:Arginine Vasopressin